Drug Comparison
CagriSema vs Exenatide: Complete Comparison
Choosing between CagriSema and Exenatide depends on your specific metabolic goals, insurance coverage, and tolerability profile. Both are weight management options, but their mechanisms, efficacy data, and cost profiles differ in clinically meaningful ways.
⚠️ Medical Disclaimer
This page is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Discuss all treatment decisions with a licensed healthcare provider who knows your complete medical history. Individual results vary significantly from clinical trial averages.
Weight Loss
CagriSema
22.7% vs 3.7%
Lower Cash Cost
Exenatide
$499/mo vs $9,999/mo
Dosing
CagriSema
Weekly vs Weekly
FDA Status
Phase 3
Approved 2005
Side-by-Side Comparison Table
| Feature | CagriSema | Exenatide |
|---|---|---|
| Brand Name(s) | Cagrilintide + Semaglutide (combination) | Byetta, Bydureon BCise |
| Mechanism | GLP-1 receptor agonist + Amylin analog (cagrilintide) | GLP-1 receptor agonist |
| FDA Status | Phase 3 | Approved 2005 |
| Mean Weight Loss | 22.7% (REDEFINE-1) | 3.7% (DURATION-1) |
| Starting Dose | 0.25 mg | 5.0 mg |
| Max Dose | 2.4 mg | 20.0 mg |
| Frequency | Weekly | Weekly |
| Half-Life | 168 hrs | 2.4 hrs |
| Cash Price/Month | N/A (investigational) | $499 |
| Prior Auth Required | No | Yes |
| Key Pivotal Trial | REDEFINE-1 | DURATION-1 |
Weight Loss Efficacy: CagriSema vs Exenatide
In their respective pivotal trials, CagriSema achieved a mean weight loss of 22.7% (REDEFINE-1) while Exenatide achieved 3.7% (DURATION-1). This 19.0 percentage point difference represents a clinically meaningful gap, though direct head-to-head trial data between these specific agents may be limited.
Important caveat: These trials enrolled different populations (different BMI criteria, T2D vs non-diabetic, different geographies) and used different primary endpoints. Direct comparisons should be interpreted with caution.
Mechanism: How They Work Differently
CagriSema is a GLP-1 receptor agonist + Amylin analog (cagrilintide). Exenatide is a GLP-1 receptor agonist. Both medications work through the GLP-1 pathway but differ in their additional receptor targets, half-lives, and molecular structures.
Side Effects
Both CagriSema and Exenatide share a similar GI side effect profile. Common side effects for both include: constipation, diarrhea, fatigue, headache. These are typically most pronounced during dose escalation and improve with time.
CagriSema-specific: Profile largely overlaps.. Exenatide-specific: Profile largely overlaps.
Cost Comparison
Cash pay prices vary significantly: CagriSema lists at approximately N/A (not commercially available) vs Exenatide at $499/month. Both require prior authorization through most commercial insurers.
Which Is Right for You? Decision Guide
Consider CagriSema if:
- ✓ Your insurance specifically covers Cagrilintide + Semaglutide (combination)
- ✓ Your prescriber has experience with CagriSema
- ✓ Once-weekly injection fits your schedule
- ✓ You have prior experience with GLP-1 receptor agonist + Amylin analog (cagrilintide) agonists
Consider Exenatide if:
- ✓ Your insurance specifically covers Byetta
- ✓ Established long-term safety data is important
- ✓ Once-weekly injection is preferred
- ✓ Simpler GLP-1 only mechanism is preferred
Bottom line: The choice between CagriSema and Exenatide is best made with your prescribing clinician, accounting for your specific medical history, insurance coverage, prior treatment response, and metabolic goals. Neither medication is universally superior for all patients.